Two strategies have been widely applied in clinical practice to treat T2DM, namely GLP-1 analogs and inhibitors of the enzyme dipeptidyl peptidase-IV (DPP-4), which degrades both GLP-1 and GIP [5]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.